Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b study of apremilast monotherapy in active psoriatic arthritis
2013-001590-25Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Apremilast 30 mg BID with Placebo (2 arms). Primary endpoint: ACR20 response at week 16. Started Aug 2013; status: completed.
02
Drugs
apremilast
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2013-001590-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001590-25.